Issue 2/2014
Content (20 Articles)
Clinical Inertia in Individualising Care for Diabetes: Is There Time to do More in Type 2 Diabetes?
William David Strain, Matthias Blüher, Païvi Paldánius
Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology
Sanjay Kalra
The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist
Stephen C. Bain
A Review of Cardiovascular Outcomes in the Treatment of People with Type 2 Diabetes
George Dailey, Edward Wang
A Randomized Trial of Step-up Treatment with Premixed Insulin Lispro-50/50 vs. Aspart-70/30 in Patients with Type 2 Diabetes Mellitus
Nozomi Domeki, Mihoko Matsumura, Tsuyoshi Monden, Yuki Nakatani, Yoshimasa Aso
Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study
Kohei Kaku, Hiroshi Maegawa, Yukio Tanizawa, Arihiro Kiyosue, Yumiko Ide, Takuto Tokudome, Yuji Hoshino, Jisin Yang, Anna Maria Langkilde
Insulin Degludec Versus Insulin Glargine in Type 1 and Type 2 Diabetes Mellitus: A Meta-Analysis of Endpoints in Phase 3a Trials
Jiten Vora, Torsten Christensen, Azhar Rana, Steve C. Bain
Increased Risk of Severe Hypoglycemic Events with Increasing Frequency of Non-severe Hypoglycemic Events in Patients with Type 1 and Type 2 Diabetes
Seamus Sreenan, Marc Andersen, Brian Larsen Thorsted, Michael L. Wolden, Marc Evans
Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?
Bo Ahrén, James Edward Foley, Sylvie Dejager, Mouna Akacha, Qing Shao, Guenter Heimann, Markus Dworak, Anja Schweizer
Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data
Sarah Bujac, Angelo Del Parigi, Jennifer Sugg, Susan Grandy, Tom Liptrot, Martin Karpefors, Chris Chamberlain, Anne-Marie Boothman
Effectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data
Zdravko Kamenov
Glucagon-Like Peptide-1 Receptor Agonist Treatment Patterns Among Type 2 Diabetes Patients in Six European Countries
Victoria Divino, Mitch DeKoven, Shawn Hallinan, Nebibe Varol, Sara Bruce Wirta, Won Chan Lee, Matthew Reaney
A Post Hoc Analysis of HbA1c, Hypoglycemia, and Weight Change Outcomes with Alogliptin vs Glipizide in Older Patients with Type 2 Diabetes
Morgan Bron, Craig Wilson, Penny Fleck
Role of Comorbidities as Limiting Factors to the Effect of Hyperbaric Oxygen in Diabetic Foot Patients: A Retrospective Analysis
Esra A. Akgül, Jale Karakaya, Salih Aydın
Initial Experience and Evaluation of Reusable Insulin Pen Devices Among Patients with Diabetes in Emerging Countries
Balduino Tschiedel, Oscar Almeida, Jennifer Redfearn, Frank Flacke
Improving Self-Monitoring of Blood Glucose among Adults with Type 1 Diabetes: Results of the Mobile™ Study
Jane Overland, Jessie Abousleiman, Andriana Chronopoulos, Natasha Leader, Lynda Molyneaux, Christopher Gilfillan
Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK
Hayley Bennett, Phil McEwan, Klas Bergenheim, Jason Gordon
Real-World Clinical and Economic Outcomes of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Mellitus in the United States
Qian Li, Abhishek Chitnis, Mette Hammer, Jakob Langer
Cost–Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden
Aliasghar A. Kiadaliri, Ulf G. Gerdtham, Bjorn Eliasson, Katarina Steen Carlsson
Erratum to: Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study
Borje Darpo, Meijian Zhou, Jessica Matthews, Hui Zhi, Malcolm A. Young, Caroline Perry, Rickey R. Reinhardt